Marion Feuilly

Lille, 59045, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Title Not Found

Title Not Found

Journal: Therapie

Published: November 13, 2024

Methodological expectations for demonstration of health product effectiveness by observational studies.

Methodological expectations for demonstration of health product effectiveness by observational studies.

Journal: Therapie

Published: October 02, 2024

Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).

Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).

Journal: ESMO open

Published: August 30, 2023

Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI.

Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI.

Journal: Future oncology (London, England)

Published: May 03, 2023

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review.

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review.

Journal: Advances in therapy

Published: October 22, 2020

Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index.

Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index.

Journal: Neuroendocrinology

Published: June 08, 2020

Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).

Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).

Journal: Cancer

Published: April 09, 2020

A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.

A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.

Journal: PharmacoEconomics

Published: March 12, 2020

Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.

Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.

Journal: World journal of gastroenterology

Published: March 05, 2020

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).

Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).

Journal: Advances in therapy

Published: January 22, 2020

Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.

Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.

Journal: Neuroendocrinology

Published: November 15, 2019

Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.

Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.

Journal: Scandinavian journal of gastroenterology

Published: November 20, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026